Approximately 401,000 New Zealand adults are currently living with Long COVID, a prevalence rate that places the condition more than a hundred times beyond the threshold of a “rare disease.” New data from the latest New Zealand Health Survey reveals that one in 11 adults are experiencing health impacts lasting three months or longer—symptoms that cannot be explained by other diagnoses and were not present prior to their COVID-19 infection.
The scale of the impact is stark: 77.7% of New Zealanders, or roughly 3.3 million people, have contracted the virus at least once. Of those who experienced an acute infection, 11.9% developed Long COVID. Nearly half of that group (48.5%) reported they were still symptomatic at the time the survey was completed.
A disproportionate burden of illness
The data shows that Long COVID does not affect the population equally. Women are significantly more likely to report lasting symptoms, with a prevalence of 14.9% (about 1 in 7) compared to 8.5% (1 in 12) for men. This gender gap disappears among those over the age of 65, where rates are similar.
Systemic vulnerabilities also play a role. One in six Māori adults (15.5%) reported Long COVID symptoms, compared to one in nine non-Māori adults (11.3%). The impact is even more pronounced among people living with disabilities, where one in four (22.8%) experienced lasting symptoms. The burden extends to the youngest populations as well, with previous research indicating that a fifth of New Zealand children reported persisting symptoms after infection.
Recent research suggests the functional impact of Long COVID is far more severe than simple fatigue; some studies indicate its impact on a person’s life can be similar to that of a stroke or Parkinson’s disease.
Medical evidence shows that the condition can affect nearly every organ system, including the nervous, immune, and cardiovascular systems. While the most recognized symptoms are cognitive dysfunction—often described as “brain fog”—and profound fatigue, many patients suffer from post-exertional malaise (PEM), where symptoms worsen after even minimal physical or mental effort. There is also the risk of “silent” cell and organ damage that may not present immediate symptoms but could predispose individuals to future chronic illness.
Clinical Context: The “Rare Disease” Threshold
In medical terms, a “rare disease” is typically defined as affecting one in 2,000 people. With a prevalence of 9.2% among New Zealand adults, Long COVID is not a niche medical concern; its frequency is over 100 times higher than this threshold, necessitating dedicated health services and specialized resources.
The cost of institutional inaction
Despite the data, there is a growing concern regarding the government’s response. The findings from the 2025 health survey were only released after a request under the Official Information Act, and the data has been publicized primarily by the Aotearoa COVID Action coordinating group rather than Health New Zealand.
Public health advocates have urged the establishment of a coordinated response, including tailored care for symptom management, financial safety nets for those unable to work, and targeted surveillance. To date, very little of this infrastructure has been instituted. This gap in care is particularly concerning as New Zealand enters a ninth wave of infections, and evidence suggests that the risk of developing Long COVID increases with each reinfection.
Preventing new cases
While treatment remains challenging, prevention is feasible. Recent research confirms that COVID vaccines continue to meaningfully reduce both the severity of acute infection and the subsequent risk of developing Long COVID. Beyond vaccination, public health experts emphasize the importance of:

- Indoor Air Quality: Implementing better ventilation, air filtration, and specific ultraviolet lighting in public settings to reduce the spread of respiratory infections.
- Cultural Shifts: Promoting a standard of staying home when sick to limit community transmission.
The persistence of the virus and its long-term sequelae suggests that COVID-19 remains a major infectious disease in Aotearoa New Zealand, carrying significant social and economic costs through lost productivity and diminished quality of life.
Understanding the impact
Is Long COVID just prolonged fatigue?
No. It is a multi-system condition that can affect the heart, brain, and immune system, often involving cognitive impairment and post-exertional malaise.
Who is most at risk in New Zealand?
While anyone can develop the condition, the data shows higher prevalence among women, Māori adults, and people living with disabilities.
Does vaccination support prevent Long COVID?
Yes, evidence indicates that vaccination reduces the risk of developing long-term symptoms following an infection.
How can healthcare systems better integrate support for patients who are struggling with symptoms that don’t fit a traditional diagnosis?





